Novel Serotonergic Psychedelic Agents as 5-HT2A Agonists for Treating Psychosis, Mental Illness, and CNS Disorders
ACS Medicinal Chemistry Letters August 25, 2025 DOI: 10.1021/acsmedchemlett.5c00484 (opens in new tab) via OpenAlex
Summary
AI-generated from the abstractThis patent document describes new chemical compounds that act as agonists at the 5-HT2A serotonin receptor, classifying them as serotonergic psychedelic agents. It claims pharmaceutical compositions containing these compounds and their use in treating psychosis, mental illness, and other central nervous system disorders. The document also outlines processes for synthesizing these compounds. The claims are technical and legal in nature, asserting novel chemical entities and their potential therapeutic applications, but no experimental data, clinical results, or evidence of efficacy are provided in this text.
Study at a glance
| Characteristics | Patent Peer reviewed |
|---|---|
| Topics | Serotonin |
| Keywords | Psychosis Psychiatry Mental illness Neuroscience |
| Key finding | Argues that novel 5-HT2A agonist compounds can be used in pharmaceutical compositions to treat psychosis, mental illness, and CNS disorders. |
Abstract
High Resolution Image Download MS PowerPoint Slide Provided herein are novel serotonergic psychedelic agents as 5-HT2A agonists, pharmaceutical compositions, use of such compounds in treating psychosis, mental illness and central nervous system (CNS) disorders, and processes for preparing such compounds.